Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.
Vaxil Bio Ltd (VXLLF) - Total Assets
Latest total assets as of September 2025: $675.00K USD
Based on the latest financial reports, Vaxil Bio Ltd (VXLLF) holds total assets worth $675.00K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaxil Bio Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Vaxil Bio Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vaxil Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Vaxil Bio Ltd's total assets of $675.00K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Vaxil Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxil Bio Ltd's current assets represent 100.0% of total assets in 2024, an increase from 46.0% in 2013.
- Cash Position: Cash and equivalents constituted 61.1% of total assets in 2024, up from 17.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vaxil Bio Ltd Competitors by Total Assets
Key competitors of Vaxil Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vaxil Bio Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vaxil Bio Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vaxil Bio Ltd is currently not profitable relative to its asset base.
Vaxil Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 75.38 | 10.00 | 1.91 |
| Quick Ratio | 75.38 | 10.00 | 1.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $595.00K | $ 738.00K | $ 777.00K |
Vaxil Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Vaxil Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.47 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -24.9% |
| Total Assets | $733.00K |
| Market Capitalization | $20.69K USD |
Valuation Analysis
Below Book Valuation: The market values Vaxil Bio Ltd's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vaxil Bio Ltd's assets decreased by 24.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaxil Bio Ltd (2013–2024)
The table below shows the annual total assets of Vaxil Bio Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $733.00K | -24.90% |
| 2023-12-31 | $976.00K | -36.66% |
| 2022-12-31 | $1.54 Million | -32.56% |
| 2021-12-31 | $2.29 Million | +37.57% |
| 2020-12-31 | $1.66 Million | +710.24% |
| 2019-12-31 | $205.00K | -76.97% |
| 2018-12-31 | $890.00K | +187.10% |
| 2017-12-31 | $310.00K | -74.53% |
| 2016-12-31 | $1.22 Million | +319.66% |
| 2015-12-31 | $290.00K | +40.42% |
| 2014-12-31 | $206.52K | -88.46% |
| 2013-12-31 | $1.79 Million | -- |